Cancer Treatment Using Bosentan in Combination with Checkpoint Inhibitors

JP2023554554A5Active Publication Date: 2024-12-17MATERIA THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023559974
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-11
Filing Date
2021-12-09
Publication Date
2024-12-17
Estimated Expiration
2041-12-09

Smart Images

  • Figure 00000071_0000
    Figure 00000071_0000
  • Figure 00000071_0001
    Figure 00000071_0001
  • Figure 00000071_0002
    Figure 00000071_0002
Patent Text Reader

Abstract

The present invention is directed to a combination treatment using bosentan and a checkpoint inhibitor that is effective in treating cancer or inhibiting tumor cell growth in a subject and / or that can elicit, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on the ability of T cells to migrate into tumors and migrate adjacent to malignant cells to recognize and kill them. The present invention provides a means to solve this problem.
Need to check novelty before this filing date? Find Prior Art